Glycoconjugate composition of colorectal goblet cell mucin was characterized according to the anatomical distribution of lectinbinding sites in mucosal biopsies from 35 control subjects and 55 patients with inflammatory bowel disease. 24 of the controls had mucosal inflammation on biopsy, without clinical evidence of inflammatory bowel disease. These inflamed controls showed a similar rate of presence of lectin-binding sites as the normal noninflamed group. In the controls, the frequency of binding of Ricinus communis agglutinin I to galactosyl residues was consistently higher than that found with either Ulex europaeus agglutinin I to fucosyl or Dolichus biflorus agglutinin to Nacetyl galactosyl groups. A significant proximal to distal gradient for Ulex europaeus agglutinin I binding sites was identified in the control group. These binding sites were present four times more often in the proximal colon than in the distal colon (P < 0.025). In the ulcerative and Crohn's colitis groups, this gradient effect was lost, predominantly as a result of decreased availability of fucosyl residues in the proximal colon. In the descending colon of Crohn's colitis tissues, there was a complete absence of Dolichus biflorus agglutinin binding sites compared with the 62.5% incidence in the control group (P < 0.05). These results demonstrate that the expression of lectin-binding sites in human large intestinal goblet mucin is specifically altered in inflammatory bowel disease, indicating that there are changes in glycosylation of colorectal mucin consistent with alterations in goblet cell differentiation.
Introduction
Characterization of the biochemical abnormalities in the colonic mucosa of patients with inflammatory bowel disease has been attempted using a number of different techniques. Histochemical studies of colorectal mucin have demonstrated a decrease in goblet cell mucin in ulcerative colitis, but no specific qualitative difference between ulcerative colitis, Crohn's colitis, and normal patients (1, 2) . Although increased sialomucin staining occurs when dysplastic changes are present (3), this does not seem to be clinically significant, since nonspecific increases in sialomucins, sulphomucins, and neutral muco-substances may all be found in inflammatory bowel disease (4) . The increase in superficial goblet cells, along with a higher percentage containing neutral mucin in the sigmoid region of ulcerative colitis patients, is thought to result from the faster cell turnover rate (5) known to occur in this disease (6, 7) . However, in severe cases of ulcerative colitis, goblet cells with neutral mucin are decreased or totally absent (5) .
Another approach involves the biochemical characterization of colonic mucosal glycoproteins, which form a major constituent of intestinal mucin (8) . Measurements of enzymes important in intestinal glycoprotein metabolism have not shown any differences in glycosyltransferase activity in patients with inflammatory bowel disease (9) , whereas glucosamine synthetase, a rate-limiting enzyme in glycoprotein synthesis, is increased in normal-appearing rectal mucosa from patients with Crohn's Disease (10). Analyses of human colonic mucus glycoproteins revealed significant reductions in both the carbohydrate content and size of the oligosaccharide units in granulomatous and ulcerative colitis (1 1). Furthermore, there is also a specific increase in the mannose-containing glycoprotein of colonic mucus in ulcerative colitis (12) . More recently, a comparison of partially purified colonic mucin from patients with inflammatory bowel and control patients identified six distinct mucin species. In ulcerative colitis, there was a selective reduction of species IV from sigmoid and ascending colon when compared with control or Crohn's Disease patients (13) .
Human mucin glycoconjugate composition also has been examined using lectins (14) . These are agglutinins that bind to specific terminal carbohydrates of glycoconjugates and have been used as specific probes to examine the structural and secretory components of human small (15) 
Results
Although the intensity of fluorescence observed was graded for each slide, such a subjective semiquantitative assessment might not be reproducible by other observers. Therefore, the data were analyzed only to determine the rate of presence of lectin-binding sites. This was achieved by classifying biopsies either as being completely devoid of lectin-binding sites (grade 0), or as exhibiting the presence of lectin-binding sites (grades 1 + or greater). The control group of biopsies was divided into inflamed and noninflamed tissues, according to previous pathological interpretation. The 10 goblet cells/crypt, with at least half the total crypts/field demonstrating lectin-binding. *P < 0.05; **P < 0.025; ***P < 0.01-P < 0.005, for UEA, and DBA groups when compared with RCA1 positive biopsies. o, UEA1; *, RCA,; m, DBA.
In the three most proximal regions of the colon, the frequency of RCA1 binding was 100%, dropping to 81.3% in the sigmoid colon, and 70.6% in the rectum. With UEA1 (Fig. 2 A) , although a similar gradient of binding sites was present, the frequency of staining was much lower, 50% of controls having available binding sites in the three most proximal portions of the intestine, compared with 18.8% in the sigmoid, and only 12.5% in the rectum. In contrast to the regional gradient of lectin-binding sites demonstrated for RCAI and UEA, (maximal binding in the proximal colon and minimum binding in the rectosigmoid), the pattern for DBA binding showed no evidence of such a gradient effect. In the proximal colon, the frequency of subjects with positive DBA staining was <20%, while maximal binding was observed in the descending colon with 62.5% of subjects showing positive lectin staining, and less than a 25% positive rate in the rectosigmoid. The frequency of DBA staining was significantly lower than that found with RCAI in all regions except the descending colon (P < 0.025 or better), while the frequency of UEA1 staining was lower than that with RCAI only in the descending colon, sigmoid, and rectum (P < 0.005).
A higher frequency of RCAI binding to colorectal mucin was also observed when ulcerative (Fig. 2 B) and Crohn's colitis (Fig. 2 C) samples were studied. In ulcerative colitis (Fig. 2 B) , the frequency of RCA1 binding was significantly higher than that of UEA, or DBA in all five regions of the intestine examined (P < 0.05 or better). In Crohn's colitis (Fig.  2 C) , the frequency of RCA1 binding to mucin was significantly higher than that of UEA1 in all regions except the descending colon (P < 0.025 or better), and significantly greater than with DBA1 in all regions except the transverse colon (P < 0.05 or better). In both forms of colitis (Figs. 2 B and C) , the existence of a proximal-to-distal gradient in lectin-binding was much less evident than that found for the control group (Fig. 2 A) .
In all three sets of patients studied (Fig. 2) , lectin-binding frequencies in the ascending and transverse regions of the proximal colon were not significantly different. Similarly, the two most distal segments (sigmoid and rectum) revealed comparable patterns and levels of lectin-binding. For these reasons, biopsies from the two most proximal and two most distal segments were pooled and designated as constituting the proximal and distal colon, respectively. Using this anatomical definition, the results for UEAI-binding to control biopsies were further analyzed, as shown in Fig. 3 A. This confirmed the impression gained from Fig. 2 A that there was a significant gradient in the frequency of lectin-binding between the proximal and distal colon. In the proximal colon, 58.3% of the biopsies were positive, compared with 14.3% in the distal colon (P < 0.025). Although there was also evidence of a proximal-todistal gradient in ulcerative and Crohn's colitis (Fig. 3 A) , this was much less marked than in the control patients, and was not statistically significant. A similar analysis for the results of RCA1 (Fig. 3 B) and DBA (Fig. 3 C) binding demonstrated that lectin-binding in all groups was greater in the proximal than in the distal colon. However, none of these differences was statistically significant.
Because biopsies from the area of the descending colon showed lectin-binding characteristics that were sometimes dissimilar from those observed in the proximal or distal colon (Fig. 2) , these data were analyzed separately (Fig. 4) . The results showed that with UEA1, 50% of the control subjects demonstrated positive lectin-binding, compared with 44.4% in the ulcerative colitis, and 20% in the Crohn's colitis groups. With RCA1, 100% of the control and ulcerative colitis subjects showed positive lectin-binding, compared with 80% of the Crohn's patients. With DBA, 62.5% of the control group and 40% of the ulcerative colitis group showed positive binding, ) and distal (open bars) colorectal mucin from control subjects and patients with inflammatory bowel disease. Lectin binding and its analysis was performed as described in Fig. 2 (24, 25) and dysplasia (3) are not present when the disease is in remission, and are not found in areas of reparative hyperplasia (24, 25) . Note that none of the ulcerative colitis patients in the present study had any history or evidence of colorectal cancer.
It is generally accepted that there is a sequential scheme for goblet cell mucin glycosylation, in which carbohydrate residues such as Fuc, Gal, and GalNAc may be added terminally (26) . However, expression of these terminal carbohydrate residues may be further modified by the enteric microflora, which have been shown to extensively degrade mucin carbohydrate moieties (27) . Thus, the final availability of lectinbinding sites in human colorectal mucin seems to be determined not only by biosynthetic factors, but also by those that produce degradation. As a result of the more rapid rate of cell turnover in inflammatory bowel disease (6, 7), less time may be available to allow full differentiation of mucin, thus resulting in a relative reduction in certain terminal carbohydrate residues such as fucose. This might also explain the decreased rate of presence of UEA, binding sites in the proximal colon of Crohn's and ulcerative colitis, resulting in a loss of the normal proximal-to-distal gradient of mucin fucosyl expression.
The results of the present study add further weight to the growing body of evidence that indicates that there are specific biochemical alterations in the colorectal mucin of patients with Crohn's and ulcerative colitis. Whether these changes are the basis or simply just another manifestation of the disease process still remains to be determined.
